Arrowhead Pharmaceuticals Inc [ARWR] stock is trading at $19.71, down -0.25%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ARWR shares have gain 9.20% over the last week, with a monthly amount drifted -3.19%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Arrowhead Pharmaceuticals Inc [NASDAQ: ARWR] stock has seen the most recent analyst activity on June 05, 2024, when Goldman initiated its Neutral rating and assigned the stock a price target of $31. Previously, BofA Securities started tracking the stock with Buy rating on December 04, 2023, and set its price target to $29. On September 19, 2023, Citigroup initiated with a Neutral rating and assigned a price target of $33 on the stock. TD Cowen started tracking the stock assigning a Outperform rating. SVB Securities downgraded its rating to a Market Perform but $40 remained the price target by the analyst firm on May 12, 2023. SMBC Nikko started tracking with a Outperform rating for this stock on April 26, 2023, and assigned it a price target of $80. In a note dated April 12, 2023, SVB Securities upgraded an Outperform rating on this stock and boosted its target price from $21 to $35.
Arrowhead Pharmaceuticals Inc [ARWR] stock has fluctuated between $17.05 and $36.72 over the past year. Currently, Wall Street analysts expect the stock to reach $26.99 within the next 12 months. Arrowhead Pharmaceuticals Inc [NASDAQ: ARWR] shares were valued at $19.71 at the most recent close of the market. An investor can expect a potential return of 36.94% based on the average ARWR price forecast.
Analyzing the ARWR fundamentals
Arrowhead Pharmaceuticals Inc [NASDAQ:ARWR] reported sales of 3.55M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at -2.82% with Operating Profit Margin at -169.27%, Pretax Profit Margin comes in at -172.48%, and Net Profit Margin reading is -168.82%. To continue investigating profitability, this company’s Return on Assets is posted at -0.53, Equity is -2.07 and Total Capital is -0.58. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.75.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 19.41 points at the first support level, and at 19.10 for the second support level. However, for the 1st resistance point, the stock is sitting at 20.02, and for the 2nd resistance point, it is at 20.32.
Ratios To Look Out For
For context, Arrowhead Pharmaceuticals Inc’s Current Ratio is 6.74. Further, the Quick Ratio stands at 6.74, while the Cash Ratio is 1.0. Considering the valuation of this stock, the price to sales ratio is 690.87, the price to book ratio is 13.22.
Transactions by insiders
Recent insider trading involved Hamilton James C, Chief Discovery/Trans Medicine, that happened on Jan 06 ’25 when 32729.0 shares were sold. COO and General Counsel, O’Brien Patrick completed a deal on Jan 06 ’25 to sell 29184.0 shares. Meanwhile, COO and General Counsel O’Brien Patrick sold 8000.0 shares on Jan 07 ’25.
